Indoxacarb

Verify with FDA CVM →

50 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
50
Total Reports
1
Deaths Reported
200.0%
Death Rate

Active Ingredients

Indoxacarb

Administration Routes

TopicalUnknownOralCutaneous

Species Affected

Dog 36
Cat 14

Most Affected Breeds

Domestic Shorthair 10
Domestic Mediumhair 3
Retriever - Golden 3
Shepherd Dog - German 3
Dog (other) 3
Retriever - Labrador 2
Chihuahua 2
Terrier - Bull - American Pit 2
Terrier - Rat 2
Cat (unknown) 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 10
Emesis 8
Anorexia 5
Lack of efficacy - NOS 5
Vomiting 5
Lack of efficacy (ectoparasite) - flea 4
Other abnormal test result NOS 4
INEFFECTIVE, HEARTWORM LARVAE 4
Ataxia 3
Anaemia NOS 3
Gagging 2
UNPALATABLE 2

Outcome Breakdown

Outcome Unknown
25 (50.0%)
Recovered/Normal
15 (30.0%)
Ongoing
9 (18.0%)
Euthanized
1 (2.0%)

Data Summary

Metric Value
Total adverse event reports 50
Reports involving death 1
Case-fatality rate (reported events) 200.0%
Distinct species in reports 2
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Indoxacarb Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 50 adverse event reports referencing Indoxacarb, including 1 reports in which the animal died — a 200.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Indoxacarb. Reported administration routes include Topical, Unknown, Oral, Cutaneous. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Indoxacarb reports are Dog (36 reports), Cat (14 reports), with Dog accounting for the largest share. Within those species, Domestic Shorthair (10), Domestic Mediumhair (3), Retriever - Golden (3) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Indoxacarb are Lethargy (see also Central nervous system depression in 'Neurological') (10), Emesis (8), Anorexia (5), Lack of efficacy - NOS (5). Of the 50 reports with a coded outcome, Outcome Unknown is the leading category at 50.0%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Indoxacarb.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial